Trial Profile
A Well-Controlled, Fixed-Dose Study of TEV 50717 (Deutetrabenazine) for the Treatment of Tics Associated with Tourette Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms ARTISTS2
- Sponsors Teva Branded Pharmaceutical Products R&D
- 19 Feb 2020 Primary endpoint has not been met. (Change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS)), according to a Teva Pharmaceutical Industries media release.
- 19 Feb 2020 Results published in the Teva Pharmaceutical Industries Media Release
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.